Showing 1701-1710 of 2526 results for "".
- Inflammasome Therapeutics Announces Positive Topline Data from K8 Implant Trial for GAhttps://modernod.com/news/inflammasome-therapeutics-announces-positive-topline-data-from-k8-implant-trial-for-geographic-atrophy/2482621/Inflammasome Therapeutics reported 3-month results from a clinical trial of its K8 implant in patients with geographic atrophy (GA). The study, conducted at the University of Kentucky (NCT06164587), demonstrated significant efficacy and safety following a single inject
- Rayner Announces Full Commercial Launch of RayOne Galaxy and RayOne Galaxy Torichttps://modernod.com/news/rayner-announces-full-commercial-launch-of-rayone-galaxy-and-rayone-galaxy-toric/2482617/After unveling the RayOne Galaxy and RayOne Galaxy Toric IOLs at the ESCRS congress in Barcelona, Rayner announced the full commercial release of the IOLs today. The launch comes following a large-scale multi
- Specialty Contact Lens Division WAVE Eye Care Formedhttps://modernod.com/news/specialty-contact-lens-division-wave-eye-care-formed/2482616/EyePrint Prosthetics, Advanced Vision Technologies (AVT), and WAVE Contact Lens System—three providers of specialty contact lens fitting—have united to form WAVE Eye Care, a division dedicated to providing fully customized specialty contact lenses. According to a j
- Altris AI Introduces AI-Powered Fluid and GA Quantification Featureshttps://modernod.com/news/altris-ai-introduces-ai-powered-fluid-and-ga-quantification-features/2482606/Altris AI, which utilizes artificial intelligence for OCT scan analysis, has unveiled additional quantification features for fluids and geographic atrophy (GA) tracking on its web platform. Altris AI currently detects more than 70 retina pathologies and biomarkers. The platform'
- Lumibird Medical Rebrands its Japanese Subsidiaryhttps://modernod.com/news/lumibird-medical-rebrands-its-japanese-subsidiary/2482598/Lumibird Medical has announced the rebranding of its Japanese subsidiary. Formerly known as Ellex Japan, the company will now operate under the name Lumibird Medical Japan, effective immediately. Founded in Osaka in 2003, the subsidiary has grown over the past two decades,&nbs
- Scientists Explore Regrowth of Optic Nerves as Potential Treatment for Glaucomahttps://modernod.com/news/scientists-explore-regrowth-of-optic-nerves-as-potential-treatment-for-glaucoma/2482591/University of Connecticut scientists have published a report in the September issue of Experimental Neurology, showing injured optic nerves can regrow towards the brain if treated properly. Blunt trauma to t
- ViaLase and the John A. Moran Eye Center Partner to Accelerate Glaucoma Research and Innovationhttps://modernod.com/news/vialase-and-the-john-a-moran-eye-center-announce-research-partnership-to-accelerate-glaucoma-research-and-innovation/2482573/ViaLase announced a research partnership with the John A. Moran Eye Center at the University of Utah, home to the Alan S. Crandall Center for Glaucoma Innovation. The collaboration will explore aqueous outflow dynamics of ViaLase’s ViaLase laser procedure, utilizing Moran’s iPerf
- The Centre for Eye and Vision Research and SCOPE Health Partner to Innovate Ocular Surface Disease Solutionshttps://modernod.com/news/the-centre-for-eye-and-vision-research-and-scope-health-partner-to-innovate-ocular-surface-disease-solutions/2482571/The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. have signed a Memorandum of Understanding (MoU) to collaborate on technologies to treat dry eye disease and other ocular surface conditions. The partnership aims to address unmet needs in eye care by leveraging SCOPE&rs
- UC Irvine Scientists Find DNA Damage is Key Factor in AMDhttps://modernod.com/news/uc-irvine-scientists-find-dna-damage-is-key-factor-in-amd/2482569/Accumulated DNA damage in the retina is a key contributor to age-related macular degeneration (AMD) and that targeting specific retinal cell types may lead to treatments that slow or stop progression, according to a research team co-led by the University of California, Irvine. The
- Scientists Use Gene Editing to Treat Retinitis Pigmentosa in Micehttps://modernod.com/news/scientists-use-gene-editing-to-treat-retinitis-pigmentosa-in-mice/2482558/Researchers funded by the National Eye Institute (NEI) have successfully used a gene-editing technique to correct a mutation responsible for retinitis pigmentosa (RP). The study, led by Krzysztof Palczewski, PhD, of the University of California